- New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
- Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion.
- Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV).
‘Who Do I Sue?’ JPMorgan Exec Sees Public Blockchains As Inadequate For Large Transactions
Public blockchains, the technology underpinning cryptocurrencies like Bitcoin (CRYPTO: BTC), may not be mature enough to handle the demands of large financial transactions, ac
